Analysts Expect ChemoCentryx Inc (CCXI) to Post -$0.25 EPS
Wall Street brokerages expect ChemoCentryx Inc (NASDAQ:CCXI) to post ($0.25) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for ChemoCentryx’s earnings, with estimates ranging from ($0.29) to ($0.18). ChemoCentryx reported earnings per share of ($0.13) in the same quarter last year, which suggests a negative year over year growth rate of 92.3%. The business is expected to report its next earnings report on Tuesday, November 6th.
On average, analysts expect that ChemoCentryx will report full year earnings of ($0.86) per share for the current fiscal year, with EPS estimates ranging from ($0.93) to ($0.73). For the next year, analysts expect that the firm will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.83) to ($1.09). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. ChemoCentryx had a return on equity of 39.31% and a net margin of 18.69%. The firm had revenue of $15.02 million during the quarter, compared to analyst estimates of $16.88 million.
In related news, insider Plc Glaxosmithkline sold 7,343,492 shares of the firm’s stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $11.69, for a total transaction of $85,845,421.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 14.50% of the stock is owned by company insiders.
A number of hedge funds have recently bought and sold shares of CCXI. Dimensional Fund Advisors LP bought a new position in ChemoCentryx during the 2nd quarter valued at approximately $4,232,000. Acadian Asset Management LLC increased its position in ChemoCentryx by 42.4% during the 2nd quarter. Acadian Asset Management LLC now owns 743,298 shares of the biopharmaceutical company’s stock valued at $9,789,000 after buying an additional 221,434 shares in the last quarter. BlackRock Inc. increased its position in ChemoCentryx by 6.0% during the 2nd quarter. BlackRock Inc. now owns 2,721,938 shares of the biopharmaceutical company’s stock valued at $35,847,000 after buying an additional 155,172 shares in the last quarter. American Century Companies Inc. increased its position in ChemoCentryx by 423.9% during the 2nd quarter. American Century Companies Inc. now owns 163,871 shares of the biopharmaceutical company’s stock valued at $2,158,000 after buying an additional 132,592 shares in the last quarter. Finally, Spark Investment Management LLC increased its position in ChemoCentryx by 161.8% during the 2nd quarter. Spark Investment Management LLC now owns 163,900 shares of the biopharmaceutical company’s stock valued at $2,158,000 after buying an additional 101,300 shares in the last quarter. 53.18% of the stock is owned by institutional investors.
Shares of NASDAQ:CCXI traded down $0.28 during trading on Friday, hitting $11.41. The stock had a trading volume of 150,797 shares, compared to its average volume of 355,861. ChemoCentryx has a 12 month low of $5.42 and a 12 month high of $15.08. The firm has a market capitalization of $588.12 million, a P/E ratio of 31.69 and a beta of 1.54. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.69 and a current ratio of 2.69.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.